Edition:
India

AbbVie Inc (ABBV.N)

ABBV.N on New York Stock Exchange

80.58USD
12:41am IST
Change (% chg)

$-0.76 (-0.93%)
Prev Close
$81.34
Open
$81.30
Day's High
$81.75
Day's Low
$80.28
Volume
682,200
Avg. Vol
1,919,239
52-wk High
$114.94
52-wk Low
$75.77

Select another date:

Fri, Jan 25 2019

UPDATE 3-AbbVie expects steeper decline in Humira's overseas sales; shares fall

Jan 25 AbbVie Inc said on Friday it expects a steeper decline in overseas sales of its top-selling drug, Humira, due to intense competition from cheaper versions in Europe, driving its shares down nearly 7 percent.

AbbVie not contemplating big deals - CEO

Jan 25 AbbVie Inc is not considering a big merger or an acquisition, Chief Executive Officer Richard Gonzalez said on Friday, allaying speculations of the company launching a bid for Bristol-Myers Squibb.

AbbVie profit misses as Humira faces biosimilar challenge in Europe

Jan 25 AbbVie Inc on Friday posted a fourth-quarter profit that missed Wall Street estimates, as the drugmaker's top-selling drug, Humira, faces competition from cheaper rival versions in Europe.

AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

UPDATE 1-AbbVie's Imbruvica fails to meet main goal in pancreatic cancer study

Jan 18 AbbVie Inc said on Friday its blockbuster cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

AbbVie's cancer drug fails to meet main goal in late-stage study

Jan 18 AbbVie Inc said on Friday its cancer treatment in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.

Abbvie to record $4 billion impairment charges on Stemcentrx assets

Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.

Abbvie to record $4 bln impairment charges on Stemcentrx assets

Jan 4 Abbvie Inc on Friday said https://bit.ly/2F9iUlb it will record an estimated $4 billion in impairment charges related to the scrapping of its development program of Rova-T, an investigational cancer therapy.

Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial.

REFILE-Lilly says Taltz superior to Humira in late-stage psoriatic arthritis trial

Dec 17 Eli Lilly and Co said on Monday its psoriatic arthritis drug, Taltz, was found to be more effective than the world's best-selling prescription medicine, AbbVie Inc's Humira, in a late-stage trial.

Select another date: